View all newsletters
Receive our newsletter – data, insights and analysis delivered to you
  1. Uncategorised
April 7, 2020

Coronavirus company news summary

By Allie Nawrat

7 April 2020

Inovio Pharmaceuticals has received approval from the US Food and Drug Administration (FDA) to commence a Phase I clinical trial of its DNA vaccine candidate INO-4800 for Covid-19 in healthy participants. The trial will assess INO-4800 in up to 40 healthy adults, with initial immune responses and safety data expected in the coming months. Read the full story here.

Takeda Pharmaceutical and its partner CSL Behring have teamed up with Biotest, BPL, LFB and Octapharma to develop a plasma-derived hyperimmune therapy to treat Covid-19. The aim of the collaboration is to immediately create an unbranded polyclonal hyperimmune immunoglobulin drug for serious complications associated with the novel coronavirus infection. Read the full story here

India has lifted restrictions on the export of nearly 25 pharmaceutical ingredients and medicines, including hydroxychloroquine, which has been sought by the US for Covid-19 treatment. The restrictions were implemented in March to ensure India did not experience drug shortages during the ongoing coronavirus pandemic.

A statistician at Lancaster University in the UK has reported that HIV drugs lopinavir/ritonavir showed promise in a clinical trial performed in Wuhan, China, which assessed the treatment’s ability to relieve Covid-19 symptoms. Participants at the Jin Yin-Tan Hospital in Wuhan were given either standard of care or lopinavir/ritonavir, with the HIV drugs leading to faster clinical improvements.

Related Companies

Topics in this article:
NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy